Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
entrez:
9
2
2019
pubmed:
9
2
2019
medline:
21
3
2019
Statut:
ppublish
Résumé
Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC).We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. The reference lists of the retrieved studies were investigated.Three publications involving a total of 1709 patients were used in the analysis. We found that overall survival (OS) (P = .25) was not statistically significant in the comparison. Safety assessments indicated custirsen were often associated with complications resulting from neutropenia (P < .001), anaemia (P < .001), thrombocytopenia (P < .001), and diarrhea (P = .002).Our meta-analysis shows that custirsen has no obvious effect on improving the OS of patients with mCRPC. Adverse reactions were more common among those patients treated with custirsen as compared to those treated with placebo.
Identifiants
pubmed: 30732140
doi: 10.1097/MD.0000000000014254
pii: 00005792-201902080-00021
pmc: PMC6380863
doi:
Substances chimiques
OGX-011
0
Thionucleotides
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14254Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
J Clin Oncol. 2010 Sep 20;28(27):4247-54
pubmed: 20733135
Onco Targets Ther. 2013 Jun 25;6:785-97
pubmed: 23836992
J Exp Clin Cancer Res. 2011 Dec 20;30:113
pubmed: 22185350
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Urology. 2006 Jan;67(1):105-9
pubmed: 16413343
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Mol Cancer Res. 2010 Jan;8(1):119-30
pubmed: 20068069
Future Oncol. 2018 Apr;14(10):907-917
pubmed: 29260582
Biochemistry. 2000 Dec 26;39(51):15953-60
pubmed: 11123922
Clin Cancer Res. 2000 May;6(5):1655-63
pubmed: 10815883
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
J Biol Chem. 1999 Mar 12;274(11):6875-81
pubmed: 10066740
Br J Cancer. 2012 Jun 5;106(12):1945-52
pubmed: 22588555
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Nat Cell Biol. 2005 Sep;7(9):909-15
pubmed: 16113678
Technol Cancer Res Treat. 2006 Dec;5(6):573-8
pubmed: 17121433
Mol Cancer Ther. 2004 Mar;3(3):223-32
pubmed: 15026542
Prostate Cancer Prostatic Dis. 2004;7(3):243-8
pubmed: 15343364
BJU Int. 2008 Aug;102(3):389-97
pubmed: 18336596
EMBO Mol Med. 2015 Apr 20;7(7):878-94
pubmed: 25896606
Ann Oncol. 2015 Feb;26(2):368-74
pubmed: 25425475
Clin Cancer Res. 2011 Sep 1;17(17):5765-73
pubmed: 21788353
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:47-57
pubmed: 16273354
Curr Oncol Rep. 2013 Apr;15(2):113-8
pubmed: 23266703
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Prostate. 2002 Feb 15;50(3):179-88
pubmed: 11813210
Cancer Res. 2000 Jan 1;60(1):170-6
pubmed: 10646870
Urology. 2002 Sep;60(3):516-20
pubmed: 12350509
Lancet Oncol. 2017 Nov;18(11):1532-1542
pubmed: 29033099
J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96
pubmed: 16145049
Lancet Oncol. 2017 Apr;18(4):473-485
pubmed: 28283282
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Gynecol Oncol. 2008 Mar;108(3):527-32
pubmed: 18177691
Oncogene. 2000 Dec 27;19(56):6651-9
pubmed: 11426651
J Thorac Oncol. 2012 Mar;7(3):579-86
pubmed: 22198426
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120